ClinicalTrials.gg
RecruitingNCT07039084Updated Nov 3, 2026

Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions

An interventional study of Speech-generating device and Control in Genetic Disease, Nonverbal Communication and Augmentative and Alternative Communication, sponsored by Murdoch Childrens Research Institute. Recruiting at 1 site in Australia. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Murdoch Childrens Research Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Genetic Diseases, Inborn with a site in Australia — 16 open to participants now, 21 under way, 7 of them phase 3. Genetic Diseases, Inborn · Australia.

Planned enrollment
33rd of 46
38 · median 75
Started
2025
with 2 others
No phase
4 of 52
3 open now
Primary completion
2027-05
later than 5 of 20 live
Registered
46th of 52
by date
Lead sponsor
2 of 52
Murdoch Childrens Research Institute

Among the 52 studies in Genetic Diseases, Inborn with a site in Australia, this one is the 33rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 with no phase, reaches primary completion later than 5 of the 20 other live ones, and was the 46th registered.

Genetic Diseases, Inborn

585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.

Browse Genetic Diseases, Inborn studies →

Open to participants now

16 of the 52 studies in Genetic Diseases, Inborn with a site in Australia are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Genetic Diseases, Inborn with a site in Australia, or all of them as a file.
02

Study summary

Individuals with rare genetic conditions may experience a delay or loss of developmental skills. Many have limited verbal speech. The aim of this clinical trial is to examine how well a speech-generating device supports the communication skills of participants with a rare genetic condition. The speech-generating device is a communication program loaded onto an iPad.

This is a crossover trial, meaning that each participant will receive both the treatment (device) and a control (usual care; no device) phase. The order in which each participant receives the device versus the usual care (no device) will depend on which group the participant is assigned to. The changes in communication in each phase will then be compared.

During the trial, participants can expect to complete a series of assessments and attend a total of 2 x 1-hour therapy session per week for 6 weeks.

Read the detailed description

In Australia, a disease is considered rare if it affects less than 1 in 2,000 individuals. There are over 7,000 rare genetic conditions, with three quarters affecting children. Rare diseases are often serious and progressive, presenting with ongoing health and developmental challenges, including speech and language disorders.

Augmentative and alternative communication (AAC) is one of the ways to support children with little speech and children with rare genetic conditions should have access to such tools as early as possible to maximise learning opportunities. However, the efficacy of high-tech AAC methods, such as speech generating devices, for children with rare genetic conditions have not been rigorously examined.

In this randomised cross-over trial, 38 participants with a rare genetic condition will be randomised into two groups (n=19 per group), which will determine the sequence of treatment delivery. The primary aim of this trial is to evaluate the efficacy of implementing a speech-generating device on communication outcomes compared with their usual care (i.e. no device). Change in communication will be measured using a patient-defined outcome - this outcome is a 'communicative act' chosen at the beginning of the trial with participants and their family. This means that each participant will have an individualised communication outcome which will be targeted during treatment sessions and measured in assessment sessions. The secondary aims include parent-reported communication, family impact and language/communication competence.

Each participant will complete screening, preference testing and baseline assessments about 2-4 weeks before randomisation. Further assessments will be completed before and after each phase. For each participant, the change in assessment scores between the start and the end of each period will be calculated. The mean difference in the change in total score between the two periods will then be calculated.

Each participant is expected to be involved in the study for 12 weeks after randomisation. This is split into two phases (6 weeks each). In the treatment (device) phase, each participant will receive two 1-hour therapy sessions per week, for 6 weeks, with a communication device (or 12 x 1-hour therapy within a 6-week treatment phase). The device is implemented by a qualified speech pathologist on the project team and can occur at Murdoch Children's Research Institute or at the participants' home.

The control (usual care) phase involves another 6 weeks, however, no therapy sessions are provided by the project team. Weekly phone-call or telehealth check-ins will be performed to ensure things are going smoothly.

03

Conditions studied

  • Genetic Disease
  • Nonverbal Communication
  • Augmentative and Alternative Communication
  • Rare Genetic Disease
  • Rare Genetic Disorders
04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is between the ages of 3 and 12 years, inclusive, at the time of enrolment
  • Has a diagnosis of a rare genetic disorder
  • Passes a visual-motor screening test, therefore being able to tap on an iPad spontaneously or by imitation and has adequate hearing
  • Considered "minimally verbal" with less than 50 spontaneous words (or gestalts) at baseline assessments, confirmed with the LVIS.
  • Is not currently using a speech-generating device with proficiency (i.e. using the device as a main mode of communication on a daily basis).
  • Is English-speaking or consents to therapy being conducted in English (parents will need to be able to complete the parent-reported measures in English)

Exclusion criteria

Exclusion Criteria:

  • Has an additional or dual genetic variation (as this is likely to cause multiple complications and increase variability),
  • Is extremely ill or has progressed into a later stage of their disease (i.e. child has loss of vision, hearing, fine motor skills, or is unable to adequately attend sessions due to illness),
  • This is to ensure treatment is beneficial, reduce harm and reduce attrition rates.
  • Lives outside of the state of Victoria (making it difficult for in-person appointments)
  • Inability or unwillingness of participant or legally acceptable representative to give written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • Other
    Treatment then Control

    The arm receives the intervention (device), then the control

    Device: Speech-generating device · Other: Control

  • Other
    Control then Treatment

    The arm receives the control, then the treatment (device)

    Device: Speech-generating device · Other: Control

Interventions

  • DeviceSpeech-generating device

    The device is an iPad loaded with a grid-based and speech-generating communication application - a suitable application for the participant is determined at the beginning of the trial. This device is used in all 12 therapy sessions and implemented by a qualified speech pathologist in a natural, play-based setting.

    Also known as: augmentative and alternative communication, communication device

  • OtherControl

    Participants will continue their current model of care. This means that if participants are receiving speech therapy locally, they may continue to do so given that no speech-generating device is introduced or used during this time. Participants will check in with the researching clinician at least once a week via telehealth or phone call - the aim is to stay in contact with families and reduce loss to follow-up. The clinician will also monitor treatment integrity and document any differences that may be present during this phase.

    Also known as: Usual care

06

What researchers measure

Primary outcomes

  1. Changes in the frequency of target communicative act related to the patient-defined outcome determined at the beginning of the trial

    Each participant will have specific communicative acts related to a patient-defined outcome determined at the beginning of the trial with each participant and their family. This means that each participant will have an individualised communication outcome which will be targeted during treatment sessions. The change in frequency of these specific communicative acts will be measured. The mean difference of each period (comparing the start to end of the phase) will be determined and compared between the 2 periods.

    Time frame: Baseline, Week 0, Week 6 and Week 12

Secondary outcomes

  1. Changes in overall communicative acts

    Changes in overall communicative acts measured through the difference in total number of all communicative acts observed between the two periods. This will be measured by the overall number of communicative acts observed during an assessment session regardless of the relation to the patient-defined outcome. The change in the total score between the start and the end of each period will be calculated for each participant. The mean difference in the change in total score between the two periods will then be calculated.

    Time frame: Baseline, Week 0, Week 6 and Week 12

  2. Changes in parent-reported communication via the Communication Matrix total score

    Changes in parent-reported communication skills will be measured using the Communication Matrix total score. For each participant the change in the total score between the start and the end of each period will be calculated. The mean difference in the total score between the two periods will then be calculated. The Communication Matrix allows for the quantification of reported behaviours, e.g. the total score is calculated by scoring each cell in the Matrix (each cell representing a communication behaviour at a particular level of communication). Each cell is scored with 0 (Not used), 1 (Emerging - inconsistently used) or 2 (Mastered - used proficiently at all times). These points are summed to obtain a score between 0 to 160 and a percentage is obtained to represent the proportion of communication behaviours Mastered.

    Time frame: Baseline, Week 0, Week 6 and Week 12

  3. Changes in family and caregiver impact assessed via the Family Impact of Assistive Technology Scale for Augmentative and Alternative Communication (FIATS-AAC)

    Changes in parent satisfaction, social impact and the mental health of caregivers will be assessed using the Family Impact of Assistive Technology Scale for Augmentative and Alternative Communication (FIATS-AAC). Each item is scored on a 7-point Likert scale and assigned into one of the 13 domains (Behavior, Caregiver Relief, Contentment, Doing Activities, Education, Energy, Face-to-Face Communication, Family Roles, Finances, Security, Self Reliance, Social Versatility, Supervision). The mean score for each domain (ranging between 1 to 7) are added together to produce the total score (ranging between 13 to 91). A higher domain score suggests a higher (more positive) functional level of that specific domain. The change in scores between the start and the end of each period will be calculated for each participant. The mean difference in the score between the two periods will then be calculated.

    Time frame: Baseline, Week 0, Week 6 and Week 12

  4. Changes in family and caregiver impact assessed via semi-structured interviews

    Changes in parent satisfaction, social impact and the mental health of caregivers will be assessed using a semi-structured interview as seen in Vogel et al. (2016), completed at baseline and at the end of each phase. Thematic analysis will be used to identify any themes that are present during these interviews and descriptively compare the differences identified.

    Time frame: Baseline, Week 6 and Week 12

  5. Changes in Language / Communication Competence assessed via the Low-Verbal Investigatory Survey

    Changes in the language and communication competence between the start and the end of each period for each participant will be determined via the Low-Verbal Investigatory Survey (LVIS). The survey produces a Verbal Communication score (between 0 to 15), an Alternative Communication score (between 0 to 11) and a Nonverbal Communication score (between 0 to 5). A higher score suggests greater communication competence in each of those areas. The mean differences in the LVIS scores between the two periods will then be calculated.

    Time frame: Baseline, Week 0, Week 6 and Week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ganz JB, Morin KL, Foster MJ, Vannest KJ, Genc Tosun D, Gregori EV, Gerow SL. High-technology augmentative and alternative communication for individuals with intellectual and developmental disabilities and complex communication needs: a meta-analysis. Augment Altern Commun. 2017 Dec;33(4):224-238. doi: 10.1080/07434618.2017.1373855. Epub 2017 Sep 19. PubMed 28922953 ↗
  • Nunn K, Williams K, Ouvrier R. The Australian Childhood Dementia Study. Eur Child Adolesc Psychiatry. 2002 Apr;11(2):63-70. doi: 10.1007/s007870200012. PubMed 12033746 ↗
  • Light J, McNaughton D. Communicative Competence for Individuals who require Augmentative and Alternative Communication: A New Definition for a New Era of Communication? Augment Altern Commun. 2014 Mar;30(1):1-18. doi: 10.3109/07434618.2014.885080. PubMed 30952185 ↗
  • Elvidge KL, Christodoulou J, Farrar MA, Tilden D, Maack M, Valeri M, Ellis M, Smith NJC; Childhood Dementia Working Group. The collective burden of childhood dementia: a scoping review. Brain. 2023 Nov 2;146(11):4446-4455. doi: 10.1093/brain/awad242. PubMed 37471493 ↗

Individual participant data

Plan to share: Yes — The de-identified data set collected for the analysis of this trial will be made available 12 months following analysis and publication of the primary outcome. The following will be made available long-term for use by future researchers from a recognised research institution: Individual participant data that underlie the results reported after anonymisation/deidentification (text, tables, figures and appendices), Trial protocol, Participant Information and Consent Form (PICF), Statistical Analysis Plan (SAP), statistical code. Note that the data sharing of de-identified speech and language data is an Optional Consent for participants.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: 12 months after publication of primary outcome

Access criteria: Interested researchers may request access to the data by submitting a formal data sharing request to the Sponsor. The request will be reviewed by the Sponsor and the Sponsor-Investigator, and any relevant Murdoch Children's Research Institute (MCRI) data sharing committee, considering factors such as scientific merit, data security, and adherence to the approved research objectives. The data may be obtained from MCRI by emailing mctc@mcri.edu.au

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 64 non-industry interventional studies with no phase under Genetic Diseases, Inborn, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 18 months is below that.

Counting every sponsor, half of 66 studies reached it within 41 months; a quarter within 22 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
Nov 3, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07039084
Lead sponsor
Murdoch Childrens Research Institute
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Nov 3, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Angela T Morgan
Contact
angela.morgan@mcri.edu.au
+61 (03) 8341 6458
Shui J Wong
Contact
jen.wong@mcri.edu.au
+61 (03) 9345 5533

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion